Rituximab-induced death of lymphoma cells
| Case . | Viability . | % spontaneous death . | % CD20-induced death . |
|---|---|---|---|
| FL1 | 80 | ≤1 | 1 |
| FL2 | 83 | 28 | ≤1 |
| FL3 | 68 | ≤1 | 31 |
| FL4 | 82 | 13 | 5 |
| FL5 | 97 | 5 | 12 |
| FL6 | 92 | 49 | ≤1 |
| FL7 | 88 | 11 | 3 |
| MCL1 | 91 | 22 | ≤1 |
| MCL2 | 91 | 32 | 3 |
| MCL3 | 90 | ≤1 | 6 |
| MCL4 | 97 | 13 | 8 |
| MCL5 | 41 | 7 | 15 |
| MCL6 | 91 | 22 | 4 |
| MCL7 | 83 | 14 | 14 |
| SLL1 | 98 | 38 | 4 |
| SLL2 | 92 | 35 | ≤1 |
| SLL3 | 91 | 8 | 3 |
| SLL4 | 87 | 18 | ≤1 |
| SLL5 | 89 | 53 | 9 |
| SLL6 | 52 | 77 | 8 |
| SLL7 | 95 | 31 | 5 |
| DLCL1 | 76 | ≤1 | 17 |
| DLCL2 | 62 | 24 | ≤1 |
| DLCL3 | 85 | 19 | 2 |
| DLCL4 | 95 | 3 | 2 |
| DLCL5 | 49 | 63 | ≤1 |
| DLCL6 | 68 | 16 | 10 |
| DLCL7 | 61 | 46 | 11 |
| NT1 | 92 | 1 | ≤1 |
| NT2 | 95 | 42 | ≤1 |
| NT3 | 91 | 22 | ≤1 |
| Case . | Viability . | % spontaneous death . | % CD20-induced death . |
|---|---|---|---|
| FL1 | 80 | ≤1 | 1 |
| FL2 | 83 | 28 | ≤1 |
| FL3 | 68 | ≤1 | 31 |
| FL4 | 82 | 13 | 5 |
| FL5 | 97 | 5 | 12 |
| FL6 | 92 | 49 | ≤1 |
| FL7 | 88 | 11 | 3 |
| MCL1 | 91 | 22 | ≤1 |
| MCL2 | 91 | 32 | 3 |
| MCL3 | 90 | ≤1 | 6 |
| MCL4 | 97 | 13 | 8 |
| MCL5 | 41 | 7 | 15 |
| MCL6 | 91 | 22 | 4 |
| MCL7 | 83 | 14 | 14 |
| SLL1 | 98 | 38 | 4 |
| SLL2 | 92 | 35 | ≤1 |
| SLL3 | 91 | 8 | 3 |
| SLL4 | 87 | 18 | ≤1 |
| SLL5 | 89 | 53 | 9 |
| SLL6 | 52 | 77 | 8 |
| SLL7 | 95 | 31 | 5 |
| DLCL1 | 76 | ≤1 | 17 |
| DLCL2 | 62 | 24 | ≤1 |
| DLCL3 | 85 | 19 | 2 |
| DLCL4 | 95 | 3 | 2 |
| DLCL5 | 49 | 63 | ≤1 |
| DLCL6 | 68 | 16 | 10 |
| DLCL7 | 61 | 46 | 11 |
| NT1 | 92 | 1 | ≤1 |
| NT2 | 95 | 42 | ≤1 |
| NT3 | 91 | 22 | ≤1 |
Lymphoma cells or NT B cells were incubated with 2 μg/mL rituximab and cell death was measured by PI incorporation after 24 hours. Viability after cryopreservation/thawing is indicated as well as spontaneous death at day 1.